Investor Visit to SN Endo

Smith & Nephew Plc
20 August 2007


Investor visit to Smith & Nephew Endoscopy

20 August 2007

Smith & Nephew plc, (LSE: SN, NYSE: SNN), the global medical technology
business, will be holding a visit for institutional investors and analysts at
the global headquarters of the company's Endoscopy business in Boston,
Massachusetts, on Tuesday 18 September 2007.

The visit will be hosted by Chief Executive, David Illingworth, and Mike
Frazzette, President of Smith & Nephew Endoscopy.  During the visit guests will
have the opportunity to meet senior management and receive presentations from
the heads of the Endoscopy business.

The main presentations of the event will be webcast live on Smith & Nephew's
corporate website at www.smith-nephew.com and will begin at 1.15pm BST/7.15am
CST/8.15am EST on Tuesday 18 September 2007.  An archive of these presentations
will be available on the website shortly after the close.


Enquiries

Julie Allen                                    Tel:       [phone]
Corporate Affairs Co-ordinator


About us

Smith & Nephew (LSE: SN.L; NYSE: SNN) is one of the world's leading medical
device companies, specialising in Orthopaedic Reconstruction, Orthopaedic Trauma
and Clinical Therapies, Endoscopy and Advanced Wound Management.  Smith & Nephew
is a global leader in arthroscopy and advanced wound management and is one of
the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives.  The company
prides itself on the strength of its relationships with its surgeon and
healthcare professional customers, with whom its name is synonymous with the
highest standards of performance, innovation and trust.  The company has over
9,600 employees and operates in 31 countries around the world, generating sales
of $2.8 billion.

Forward-Looking Statements

This press release contains certain 'forward-looking statements' within the
meaning of the US Private Securities Litigation Reform Act of 1995.  In
particular, statements regarding expected revenue growth and trading margins
discussed under 'Outlook' are forward-looking statements as are discussions of
our product pipeline.  These statements, as well as the phrases 'aim', 'plan',
'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect',
'target', 'consider' and similar expressions, are generally intended to identify
forward-looking statements.  Such forward-looking statements involve known and
unknown risks, uncertainties and other important factors (including, but not
limited to, the outcome of litigation, claims and regulatory approvals) that
could cause the actual results, performance or achievements of Smith & Nephew,
or industry results, to differ materially from any future results, performance
or achievements expressed or implied by such forward-looking statements.  Please
refer to the documents that Smith & Nephew has filed with the U.S. Securities
and Exchange Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith & Nephew's most recent annual report on Form 20F, for a
discussion of certain of these factors.

All forward-looking statements in this press release are based on information
available to Smith & Nephew as of the date hereof.  All written or oral
forward-looking statements attributable to Smith & Nephew or any person acting
on behalf of Smith & Nephew are expressly qualified in their entirety by the
foregoing.  Smith & Nephew does not undertake any obligation to update or revise
any forward-looking statement contained herein to reflect any change in Smith &
Nephew's expectation with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.



                      This information is provided by RNS
            The company news service from the London Stock Exchange